HTG Molecular to Present a Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference

September 26, 2018 at 4:01 PM EDT

TUCSON, Ariz., Sept. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, being held October 1-2, 2018 at the InterContinental New York Barclay Hotel in New York City.

HTG Molecular Diagnostics Presentation Details
Date: Tuesday, October 2, 2018
Time: 2:15pm Eastern Time
Location: InterContinental New York Barclay Hotel
  Track 6 – Rockefeller Suite

About HTG: 
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.

Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 525-7754
Email: arr@lifesciadvisors.com 

TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
Email: tjjohnson@htgmolecular.com 

HTG logo

Source: HTG Molecular Diagnostics, Inc.